Evaluating the Role of Treatment Accessibility in HIV-TB Co-Infection: A Comparative Approach Using Fractional-Order Modeling
Clinical Scorecard: Evaluating the Role of Treatment Accessibility in HIV-TB Co-Infection: A Comparative Approach Using Fractional-Order Modeling
At a Glance
| Category | Detail |
|---|
| Condition | HIV-TB Co-Infection |
| Key Mechanisms | HIV-induced immunosuppression increases the risk of TB progression; overlapping toxicities and drug interactions complicate treatment. |
| Target Population | Individuals living with HIV, particularly in low- and middle-income countries. |
| Care Setting | Resource-constrained healthcare environments. |
Key Highlights
- HIV-positive individuals are 16–27 times more likely to develop active TB.
- TB is the leading cause of death among people living with HIV.
- Integrated approaches combining HIV and TB treatment are essential for effective management.
- Multidrug-resistant TB (MDR-TB) complicates treatment efforts.
- Effective management requires addressing healthcare access and stigma.
Guideline-Based Recommendations
Diagnosis
- Early diagnosis of HIV and TB is critical.
- Use of robust diagnostic tools to identify co-infection.
Management
- Integrated treatment strategies for HIV and TB.
- Scale-up of antiretroviral therapy (ART) and TB preventive therapy.
Monitoring & Follow-up
- Regular monitoring of treatment adherence and drug interactions.
- Surveillance data to inform treatment strategies.
Risks
- Increased mortality risk due to TB among HIV-positive individuals.
- Potential for drug resistance in TB treatment.
Patient & Prescribing Data
Individuals co-infected with HIV and TB, particularly in high-burden regions.
Careful management of ART and anti-TB drugs is necessary to mitigate overlapping toxicities.
Clinical Best Practices
- Implement integrated care models for HIV and TB.
- Enhance healthcare access in low-resource settings.
- Address stigma to improve treatment adherence.
References
